[PCN334] French Health Technology Assessment Of Antineoplastic Drugs Indicated In The Treatment Of Solid Tumours: Perspective For Future Trends

[PCN334] French Health Technology Assessment Of Antineoplastic Drugs Indicated In The Treatment Of Solid Tumours: Perspective For Future Trends

2015 Value in Health

Chouaid, C. | Borget, I. | Braun, E. | Bazil, M. | Schaetz, D. | Rémuzat, C. | Toumi, M. | Volume: 18, Issue: 7, Pages: A489,

France is one of the European countries that spends the most on oncology drugs. In the context of a cost-constraint environment, Health Authorities highly scrutinize market access pathways for potentially costly medicines. This study aimed to conduct a review of the Transparency Committee (CT) opinions of antineoplastic drugs indicated for the treatment of solid tumours to assess current trends in French health technology assessment (HTA), to confront experts with outcomes of this review and discuss foreseen challenges for HTA of future antineoplastic medicines in France.

https://www.doi.org/10.1016/j.jval.2015.09.1353